Trial Profile

An Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of BEBT-908 in the Treatment of Relapsed or Refractory Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Lymphoplasmacytoid Lymphoma /Waldenstrm Macroglobulinemia, and Marginal Zone Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ifupinostat (Primary)
Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Macroglobulinaemia; Marginal zone B-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use
Sponsors BeBetter Med

03 Apr 2023 New trial record
22 Dec 2021 According to BeBetter Med media release, Guangzhou BeBetter Medicine Technology changed its name to BeBetter Med.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com